GHK-Cu (copper peptide)

1. 01Bloodstream

   A copper carrier in the blood

   Blood already contains a small amount of GHK. It grabs copper and can carry it between the blood and body tissues. How much it matters in people is not settled.

   For experts

   GHK binds Cu(II) with high affinity and competes with albumin for the metal: at equimolar concentrations about 42% of copper was on the peptide in vitro at pH 7.5 (Lau 1981), which led to the proposal that it helps move copper from blood to tissues. Review articles by the discoverer's group report a plasma level of about 200 ng/mL at age 20 falling to about 80 ng/mL at age 60; this comes from author reviews rather than a large independent cohort. In electrochemical experiments Cu(II)GHK could be reduced to Cu(I) with release of the copper ion (Hureau 2011).[src][src][src]

2. 02Skin

   Prompting skin cells to build scaffolding

   In dishes, skin-supporting cells (fibroblasts) made more collagen when GHK-Cu was added. That is cell-culture evidence, not proof it works the same way in people.

   For experts

   In fibroblast cultures, GHK-Cu stimulation of collagen synthesis began between 10^-12 and 10^-11 M and was maximal at 10^-9 M, independent of any change in cell number (Maquart 1988). In rat wound chambers the same group found a concentration-dependent rise in dry weight, DNA, total protein, collagen and glycosaminoglycan content, with increased type I and III collagen mRNAs but not TGF-beta mRNAs (Maquart 1993). These are in vitro and rodent findings.[src][src]

3. 03Skin

   Adjusting the enzymes that reshape wounds

   Wounds constantly break down and rebuild their scaffolding using enzymes. In rats, GHK-Cu changed when some of those enzymes were active. This is animal-only evidence.

   For experts

   In a rat wound-chamber model, GHK-Cu injections did not change interstitial collagenase activity but prolonged MMP-9 expression in wound tissue and increased pro-MMP-2 and activated MMP-2 at later stages (days 18 to 22), suggesting altered remodelling (Simeon 1999). In rat ischemic wounds, topical tripeptide-copper reduced wound area (day 13: 64.5% smaller vs 45.6% vehicle and 28.2% untreated) with lower TNF-alpha, MMP-2 and MMP-9 concentrations than untreated control wounds (Canapp 2003). Animal-only.[src][src]

4. 04Immune system

   Calming inflammatory signals in animal models

   In mice with lung damage, the GHK peptide lowered some inflammation and scarring signals. Nobody has shown this in patients.

   For experts

   In bleomycin-induced pulmonary fibrosis in mice, intraperitoneal GHK reduced inflammatory infiltration, TNF-alpha and IL-6 in lavage fluid, collagen deposition and MMP-9/TIMP-1 imbalance, and reversed increases in TGF-beta1, phospho-Smad2/3 and IGF-1 (Zhou 2017). These are mouse data only, and the study used the peptide named GHK; copper contribution was not the focus.[src]

5. 05Elsewhere

   Shifting which genes are switched on

   Computer searches of gene databases found that GHK pushes many genes up or down in cells. Scientists still argue about what that means for real patients.

   For experts

   Connectivity Map analysis identified GHK as a compound reversing a gene-expression signature of emphysematous lung destruction and inducing TGF-beta pathway-like patterns; in human fibroblasts GHK increased integrin beta-1 expression, organised the actin cytoskeleton and restored collagen I contraction in COPD-derived fibroblasts (Campbell 2012). A review from the discoverer's group extends this to claims that GHK alters expression of roughly a third of human genes at a 50% threshold (Pickart 2018); these are cell-line and in-silico observations without clinical confirmation.[src][src]

6. 06Skin

   What small human studies show on skin

   In people, the evidence is limited to creams and gels. One older trial in diabetic foot ulcers was positive. A small trial after laser treatment found no measurable difference, only that patients felt their skin looked better.

   For experts

   A multicentre randomised, evaluator-blinded, vehicle-controlled trial of topical GHK-copper gel in diabetic neuropathic plantar ulcers reported greater median area closure (98.5% vs 60.8%, P < 0.05) and, in ulcers treated immediately after debridement, lower infection incidence (7% vs 34%) (Mulder 1994). A 13-patient randomised trial after CO2 laser resurfacing found no significant objective difference in erythema resolution, wrinkles or skin quality; subjective overall skin quality favoured GHK-Cu (P = .04) (Miller 2006). Cosmetic cream trials of 41 to 71 women over 12 weeks are described in reviews by the discoverer's group (Pickart 2015).[src][src][src]

7. 07Brain

   Early nose-to-brain studies in mice

   One mouse study tested GHK-Cu given through the nose in a model of Alzheimer's disease. These are animal-only results and not a treatment for people.

   For experts

   In 5xFAD transgenic Alzheimer's model mice, intranasal GHK-Cu given for three months delayed cognitive impairment, reduced amyloid plaque burden and lowered MCP1-mediated inflammation in frontal cortex and hippocampus (Tucker 2024). It is a single mouse study; the authors describe it as a rationale for further studies. No human data were verified.[src]

Around the world

Is GHK-Cu (copper peptide) legal where you live?

Related molecules